State Key Laboratory of Pathogens and Biosecurity, Beijing Institute of Microbiology and Epidemiology, No. 20 Dongdajie, Fengtai District, Beijing 100071, People's Republic of China.
Can J Microbiol. 2010 Dec;56(12):1003-10. doi: 10.1139/W10-087.
Shiga toxins produced by Escherichia coli O157:H7 cause a wide spectrum of enteric diseases, such as lethal hemorrhagic colitis and hemolytic uremic syndrome. In this study, the B subunit protein of Shiga toxin type 1 (Stx1) was produced in the E. coli system, was further purified by Ni-column Affinity Chromatography method, and was then used as an immunogen to immunize laying hens for yolk immunoglobulin (IgY) production. Titers of IgY increased gradually with boosting vaccination and, finally, reached a level of 105, remaining steady over 1 year. Then the protective efficacy of IgY against Stx1 was evaluated by in vitro and in vivo experiments. It was shown that the anti-Stx1 IgY could effectively block the binding of Stx1 to the Hela cells and could protect BALB/c mice from toxin challenges. The data indicates the facility of using egg yolk IgY as a therapeutic intervention in cases of Shiga toxin intoxication.
产志贺毒素大肠杆菌 O157:H7 产生的志贺毒素 1 型（Stx1）B 亚单位蛋白在大肠杆菌系统中表达，通过 Ni 柱亲和层析法进一步纯化，然后用作免疫原免疫产蛋母鸡以产生卵黄免疫球蛋白（IgY）。IgY 的滴度随着加强免疫而逐渐增加，最终达到 105，在 1 年内保持稳定。然后通过体外和体内实验评估 IgY 对 Stx1 的保护效力。结果表明，抗 Stx1 IgY 可有效阻止 Stx1 与 Hela 细胞的结合，并可保护 BALB/c 小鼠免受毒素的攻击。数据表明，使用卵黄免疫球蛋白 IgY 作为志贺毒素中毒的治疗干预是可行的。
